No Picture
Trading Ideas

Canadian Crude Is So Cheap It Costs More to Ship Than to Buy

(Bloomberg) — Canadian heavy crude has become so cheap that the cost of shipping it to refineries exceeds the value of the oil itself, a situation that may result in even more oil-sands producers shutting operations.Western Canadian Select crude in Alberta dropped to a record low of $5.03 a barrel on Friday, according to Bloomberg data going back to 2008, cheaper than a Starbucks venti-sized pumpkin spice latte. Synthetic crude, produced from oil-sands bitumen that’s been run through an upgrader, is in even worse shape: the price tumbled 10% to $9.78 a barrel, also the lowest on record.Canadian heavy crude …read more […]

No Picture
Trading Ideas

Struggling Americans Can Tap 401Ks With Coronavirus Bill

(Bloomberg) — Lawmakers in Washington are making it easier for Americans struggling with the fallout from the coronavirus to draw on the trillions of dollars in their 401(k)s and other retirement accounts.For a limited time, Americans would be able to withdraw money from tax-deferred accounts without penalties under a stimulus package approved by the Senate and awaiting a vote in the House. Rules on 401(k) loans would also be relaxed, and some retirees would avoid so-called required minimum distribution, or RMD, rules that might have been onerous.Read more: House faces urgency to act on Senate’s $2 trillion virus rescue billSome …read more […]

No Picture
Trading Ideas

Blue Apron Staves Off Obscurity With Another 15 Minutes of Fame

(Bloomberg) — The recent popularity of Blue Apron Holdings Inc.’s mail-order meal kits is giving the struggling company a much-needed boost, but some industry watchers say that will pass once the coronavirus outbreak abates.Blue Apron is attracting new users in part because fresh ingredients can be hard to find in supermarkets right now, said Dan McCarthy, an assistant professor of marketing at Emory University’s Goizueta Business School. However, he notes the company was “bleeding customers very consistently” up until recently and that’s likely to be the case again once people return to their normal lives.“The amount of repeat business they …read more […]

Healthcare

CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation

VANCOUVER, Washington, March 27, 2020  — CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that, at the […]

Healthcare

(OTC: CYDY) Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation

IncellDx’s evaluation of test results from the first four patients suggests immunological benefit within three days following treatment with leronlimab on all four patients and lower level of cytokine storm, especially IL-6 and TNF-α, which […]